Validation of the Modified Cognitive Assessment Scale (MoCA Blind) for the Diagnosis of Postoperative Neurocognitive Disorders in Patients With Corneal Pathology in Russia.

February 19, 2026 updated by: Alexander Romanov, The S.N. Fyodorov Eye Microsurgery State Institution
Long-term observation has shown that patients with visual impairment often develop cognitive impairments. Due to the fact that patients who are planning to undergo corneal transplantation may have initial cognitive deficits, assessing cognitive function is an important aspect of work for both the anesthesiologist and the operating surgeon. Given the high significance of assessing cognitive function after anesthesia in ophthalmic surgery patients, it is relevant to adapt and validate the Russian version of the MoCA Blind test for subsequent use in clinical practice.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Alexandr Alexandr Romanov
  • Phone Number: +79182942721
  • Email: Saha_ro@mail.ru

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Russian-speaking patients with corneal pathology who are planning a corneal transplant in the future

Description

Inclusion Criteria:

  • patients with corneal pathology, including burns, ulcers, dystrophies, and keratoectasia, as well as those with a history of corneal injuries
  • physical status of I-III on the ASA scale.

Exclusion Criteria:

  • children
  • patients with sensorineural hearing loss
  • patients with chronic cerebrovascular disorders
  • patients with initially high levels of anxiety and depressive symptoms
  • patients with severe cognitive impairments.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
postoperative neurocognitive disorders
Time Frame: From the moment of inclusion in the study until the end of treatment 90 days later
Postoperative neurocognitive disorders were identified by comparing the results of neuropsychological tests performed before surgery and on the 90th day after surgery. An individual Z-score was used for each domain of the test.
From the moment of inclusion in the study until the end of treatment 90 days later

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The S.N. Fyodorov Eye Microsurgery State Institution

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

January 30, 2027

Study Registration Dates

First Submitted

February 12, 2026

First Submitted That Met QC Criteria

February 19, 2026

First Posted (Actual)

February 20, 2026

Study Record Updates

Last Update Posted (Actual)

February 20, 2026

Last Update Submitted That Met QC Criteria

February 19, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • SNF1
  • № 143 01.01.2026 (Other Identifier: the Krasnodar Branch The S.Fyodorov Eye Microsurgery Federal State Institution)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

No final decision has been made.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Neurocognitive Disorders

Clinical Trials on Neurocognitive testing

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe